SAN DIEGO, Feb. 6, 2012 /PRNewswire/ -- AltheaDx announced today that it has achieved authorized customer service provider (CSP) status in Ion Torrent's new service provider program. The CSP certification formalizes AltheaDx's extensive training and testing under the guidance of Ion Torrent personnel to produce the highest quality sequence data.
Ion Torrent has revolutionized DNA sequencing through their pioneering use of semiconductor technology and simple chemistry instead of light as an intermediary signal. Ion Torrent technology translates the chemical signals into digital information, massively increasing the speed and decreasing the cost of DNA sequencing, thus enabling applications in nucleic acid-based biomarker discovery and clinical trial support that have been heretofore unachievable.
Francois Ferre, Ph.D., CEO of AltheaDx commented that "Implementation of next-generation sequencing is a natural addition to AltheaDx's suite of nucleic acid-based testing services, where for the past 14 years we have supported our pharma partners in over 450 studies. Furthermore, the speed and ease with which we can develop and validate new customized assay designs using the Ion Personal Genome Machine (PGM™) has completely changed our approach to supporting their translational biomarker development efforts."
Joe Monforte, Ph.D., CSO, of AltheaDx added, "We are excited about the evolution of NGS platforms and their specific utility in the molecular pathology lab setting. We are already implementing this platform for use in clinical studies. The fact that LIFE has laid out a diagnostic path for the Ion Torrent device means that we can now push ahead several of our companion diagnostic programs based on NGS."
Maneesh Jain, Vice President of Marketing and Business Development at Ion Torrent indicated that "AltheaDx was among our first early access sites and now we are very pleased to have them on board not just as an Ion Torrent Authorized Customer Service Provider for the Ion PGM, but as a partner who will help extend the boundaries of Next Generation Sequencing."
About AltheaDx, Inc.:
AltheaDx, a leading San Diego-based diagnostic development and testing company, provides clinical biomarker discovery, assay development and validation services that support researchers worldwide in their efforts to utilize genomic information for the advancement of novel therapies. AltheaDx plays a critical role in helping pharma to discover and validate biomarkers that can predict drug response, and then to provide an efficient seamless commercialization path to bring the tests to market. The goal of AltheaDx is to reduce the time, risk, and cost of therapeutic development for pharma partners.
For more information, visit www.altheadx.com
About Life Technologies:
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific and medical advancements that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance the fields of discovery and translational research, molecular medicine, stem cell-based therapies, food safety and animal health, and 21st century forensics. The company manufactures both molecular diagnostic and research use only products. Life Technologies' industry-leading brands are found in nearly every life sciences lab in the world and include innovative instrument systems under the Applied Biosystems and Ion Torrent names, as well as, the broadest range of reagents with its Invitrogen, GIBCO, Ambion, Molecular Probes and Taqman products. Life Technologies had sales of $3.6 billion in 2010, has a workforce of approximately 11,000 people, has a presence in approximately 160 countries, and possesses one of the largest intellectual property estates in the life sciences industry, with approximately 3,900 patents and exclusive licenses. For more information on how we are making a difference, please visit our website: http://www.lifetechnologies.com.
CONTACT: Steven Daniel, +1-760-532-9759, email@example.com
Copyright©2010 PR Newswire.
All rights reserved